Dovitinib

Search with Google Search with Bing

Information
Drug Name
Dovitinib
Description
Entry(CIViC)
6
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
breast cancer FGFR1 AMPLIFICATION
( ENST00000425967.8 ) FGFR1 AMPLIFICATION
( ENST00000425967.8 ) 		B Predictive Supports Sensitivity/Response N/A 2 23658459 Detail
breast cancer FGFR2 AMPLIFICATION
( ENST00000457416.7 ) FGFR2 AMPLIFICATION
( ENST00000457416.7 ) 		B Predictive Supports Sensitivity/Response N/A 2 23658459 Detail
breast cancer FGF3 AMPLIFICATION
( ENST00000334134.4 ) FGF3 AMPLIFICATION
( ENST00000334134.4 ) 		B Predictive Supports Sensitivity/Response N/A 2 23658459 Detail
lung non-small cell carcinoma FGFR1 AMPLIFICATION
( ENST00000425967.8 ) FGFR1 AMPLIFICATION
( ENST00000425967.8 ) 		B Predictive Supports Sensitivity/Response Somatic 2 27315356 Detail
bladder carcinoma FGFR1 EXPRESSION FGFR1 EXPRESSION D Predictive Supports Sensitivity/Response N/A 2 21119661 Detail
bladder carcinoma FGFR3 EXPRESSION FGFR3 EXPRESSION D Predictive Supports Sensitivity/Response N/A 3 21119661 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
Dovitinib was evaluated in-vitro, in xenograft and... FGFR1 FGFR1 AMPLIFICATION
( ENST00000425967.8 ) FGFR1 AMPLIFICATION
( ENST00000425967.8 ) 		Sensitivity true CIViC Evidence detail
Dovitinib was evaluated in-vitro, in xenograft and... FGFR2 FGFR2 AMPLIFICATION
( ENST00000457416.7 ) FGFR2 AMPLIFICATION
( ENST00000457416.7 ) 		Sensitivity true CIViC Evidence detail
81 patients were enrolled in a clinical trial with... FGF3 FGF3 AMPLIFICATION
( ENST00000334134.4 ) FGF3 AMPLIFICATION
( ENST00000334134.4 ) 		Sensitivity true CIViC Evidence detail
Clinical trial studied the efficacy of Dovitinib o... FGFR1 FGFR1 AMPLIFICATION
( ENST00000425967.8 ) FGFR1 AMPLIFICATION
( ENST00000425967.8 ) 		Sensitivity true CIViC Evidence detail
One urothelial cell line (JMSU1) with high express... FGFR1 FGFR1 EXPRESSION FGFR1 EXPRESSION Sensitivity true CIViC Evidence detail
The effects of FGFR inhibitors (PD173074, TKI-258 ... FGFR3 FGFR3 EXPRESSION FGFR3 EXPRESSION Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT01223027 Completed Phase 3 Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma March 2011 June 2014
NCT01232296 Completed Phase 2 A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment July 2011 April 2014
NCT01262027 Completed Phase 2 TKI258 for Metastatic Inflammatory Breast Cancer Patients January 27, 2012 November 25, 2015
NCT01440959 Completed Phase 2 Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258 September 2011 March 2013
NCT01443481 Completed Phase 1 Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function November 2011 October 2014
NCT01514526 Completed Phase 2 Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma January 2012 November 2016
NCT01635907 Completed Phase 2 Dovitinib in Neuroendocrine Tumors June 2012 April 11, 2016
NCT01676714 Completed Phase 2 Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer February 2013 June 2016
NCT01678105 Completed Phase 2 A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands November 2012 September 2015
NCT01714765 Completed Phase 1 Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer April 2011 October 2012
NCT01719549 Completed Phase 2 Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1 September 2012 November 2016
NCT01753713 Completed Phase 2 Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma December 20, 2012 September 20, 2017
NCT01964144 Completed Phase 2 An Open-label, Multicenter, Phase II Study of Dovitinib in Advanced Thyroid Cancer January 2013 October 2014
NCT02116803 Completed Phase 2/Phase 3 An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective May 28, 2014 November 28, 2016
NCT01888965 Terminated Phase 2 Maintenance Dovitinib for Colorectal and Pancreas Cancer October 2013 October 2014
NCT01769547 Terminated Phase 2 A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy March 2013 June 2015
NCT01528345 Terminated Phase 2 Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer April 2012 April 2015
NCT01548924 Terminated Phase 1 Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors April 2012 August 2013
NCT01266070 Terminated Phase 2 TKI 258 in Von Hippel-Lindau Syndrome (VHL) November 2012 December 2015
NCT01732107 Terminated Phase 2 Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression March 2013 March 6, 2017
NCT01994590 Terminated Phase 2 Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC) May 19, 2014 June 5, 2017
NCT01484041 Terminated Phase 1/Phase 2 Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer April 2012 December 2017
NCT01972750 Unknown status Phase 1 Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma October 2013 November 2016
NCT01861197 Unknown status Phase 2 Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer March 2013
NCT01791387 Unknown status Phase 2 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC March 2012 June 2015
NCT01680796 Withdrawn Phase 1 Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma February 2013 February 2013
NCT02065323 Withdrawn Phase 2 A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT